Read Gene SA
Read Gene SA is a biotechnology company focused on pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biotechnology products.
Business. Read Gene SA is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange under the ticker symbol RDG.WA. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Read Gene SA is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange under the ticker symbol RDG.WA. Specific details regarding operating segments and geographic revenue mix are not available.
Read Gene SA has a current ratio of 10.28, indicating strong liquidity with current assets significantly outpacing current liabilities. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage. However, the company reported negative operating and net income, with operating cash flow of 164,270 PLN and free cash flow of -390,260 PLN, indicating cash flow challenges despite strong liquidity.
Profitability metrics show a return on equity of -14.32% and a return on assets of -3.64%, both significantly below the industry median for biotechnology firms. The company's operating margin is -25.63% (calculated as operating income / revenue), and its net margin is -23.84% (calculated as net income / revenue), both of which are negative and suggest operational inefficiencies or high costs relative to revenue.
Read Gene SA operates in a single business segment, with all revenue derived from its biotechnology and medical research activities. The company does not disclose geographic revenue breakdowns, but its operations are likely concentrated in its home market. This lack of geographic diversification could expose the company to regional economic or regulatory risks.
The company's revenue for the latest period was 2,119,010 PLN, with no disclosed revenue growth in the prior period. The outlook for the current fiscal year is neutral, with no significant revenue growth expected. The next fiscal year is also projected to show minimal change, with no clear drivers of growth identified in the financial data.
Risk factors include low liquidity and low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company has no long-term debt and a strong current ratio, but its negative operating and net income suggest potential cash flow constraints. There is no indication of dilution risk in the near term, as shares outstanding for both basic and diluted are the same.
Recent events include the latest financial filing, which shows a continuation of losses and negative cash flow from operations. No significant events such as mergers, acquisitions, or major regulatory changes were disclosed in the latest filing. The company's financial performance remains a key area of focus for investors.
- Read Gene SA has strong liquidity but is currently unprofitable, with negative operating and net income.
- The company's return on equity and return on assets are significantly below industry medians, indicating poor profitability.
- Read Gene SA operates in a single business segment with no disclosed geographic diversification, increasing regional risk exposure.
- The company has no long-term debt and a low dilution risk, but its negative cash flow from operations is a concern.
- No significant growth drivers or events were identified in the latest financial data.
Bull / Bear case
Generated · model-assistedRevenue grew 17.7% year-over-year to PLN 15.6 million, demonstrating strong top-line expansion momentum.
Net income surged 172.8% to PLN 808,320, marking a significant turnaround from previous losses.
Operating income improved by 366.8% to PLN 1.04 million, indicating substantial operational efficiency gains.
Free cash flow turned positive with a 201.1% increase to PLN 930,190, enhancing liquidity.
Operating and net margins outperform the biotechnology cohort median, suggesting superior relative profitability.
The company faces high credit risk, potentially impacting its ability to secure favorable financing terms.
Cash conversion ratio sits in the bottom quartile of its cohort, signaling poor cash generation efficiency.
Revenue declined significantly from FY-1 to FY-4 before recent recovery, showing historical volatility.
Long-term debt remains substantial at PLN 4.88 million, creating ongoing financial obligations.
In focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- Read Gene SA Market data — financials · 2026-05-29
Ownership & reference
Leadership
- Bronislaw ZiemianinChairman of the Supervisory Board